If you purchase this report now and we update it in next 100 days, get it free!
The United Arab Emirates has cultivated a highly sophisticated environment for psoriasis treatment marked by high-quality dermatological services, robust private healthcare systems, and swift integration of new biologic therapies. Key cities like Dubai and Abu Dhabi feature accredited hospitals and specialized dermatology clinics that deliver thorough psoriasis management utilizing the newest targeted approaches, including IL-17 and IL-23 inhibitors. The nation's emphasis on progressive medical technology and patient-focused care strategies has empowered dermatologists to implement state-of-the-art treatment methods that align with clinical standards. Patients receive comprehensive care from a team comprising dermatologists, rheumatologists, and immunologists, particularly in cases of moderate-to-severe psoriasis and psoriatic arthritis. Furthermore, medical travel significantly impacts the UAE’s dermatology field, drawing in patients from the Middle East, Africa, and Asia who are in search of superior treatment and innovative biologic alternatives. Upscale healthcare facilities provide individualized treatment strategies, state-of-the-art diagnostic resources, and specialized phototherapy options, solidifying the country's role as a regional center for skin care. The availability of private insurance and employer-funded health plans enhances access to expensive therapies, encouraging the swift use of biologics in comparison to other nearby markets. , digital health initiatives and teledermatology services are progressively being incorporated into health practices, allowing remote consultations and ongoing monitoring for both international and local patients. , the UAE’s psoriasis treatment environment exemplifies a high-end, innovation-focused model bolstered by the growth of medical tourism, substantial private healthcare investment, and a swiftly evolving clinical environment emphasizing advanced biologic therapies.
According to the research report, " UAE Psoriasis Treatment Market Overview, 2031," published by Bonafide Research, the UAE Psoriasis Treatment market is anticipated to grow at more than 11.23% CAGR from 2026 to 2031. The psoriasis sector in the UAE thrives due to high per capita healthcare expenditure and the significant involvement of international pharmaceutical firms that actively bring advanced dermatological solutions and new biologics into the local arena. Regulatory bodies such as the Ministry of Health and Prevention and the Dubai Health Authority ensure streamlined approval systems, facilitating quick incorporation of ly sanctioned therapies. Prominent pharmaceutical companies work alongside local hospitals and research institutions to bolster clinical trials, training for healthcare professionals, and education campaigns that improve treatment quality and patient results. State-of-the-art dermatology clinics outfitted with modern diagnostic systems and specialized treatment facilities play a vital role in providing customized care designed to meet the unique needs of each patient. Chances in the UAE psoriasis sector is increasingly directed towards individualized dermatology and specific biological treatments aimed at addressing particular inflammatory pathways and genetic characteristics. Techniques in precision medicine, like biomarker assessments and personalized treatment plans, are becoming more popular in private healthcare facilities. The varied expatriate community in the nation also generates a need for healthcare services that consider cultural differences and adaptable treatment choices. Moreover, collaborations between pharmaceutical firms and healthcare providers are encouraging initiatives for patient education and programs that promote adherence, which are focused on enhancing long-term management of the disease. With significant investment in healthcare infrastructure, digital health solutions, and specialized medical services, the UAE presents a vibrant setting for groundbreaking treatments and advanced models of dermatological care.
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
UAE psoriasis treatment market by type is divided into plaque psoriasis, psoriatic arthritis and others. In the UAE psoriasis market, plaque psoriasis stands out as the leading category, comprising most of the dermatology appointments in private hospitals and high-end specialized clinics. The population's high level of awareness, extensive screenings, and access to modern diagnostic tools facilitate early detection and effective treatment for plaque psoriasis. In Dubai and Abu Dhabi, dermatologists frequently utilize contemporary treatment regimens, incorporating targeted biologic therapies for moderate to severe cases, showcasing the robust healthcare system and the prevalence of private health insurance. Collaborative care approaches and individualized treatment plans enhance clinical results and long-term management of the disease. Another important category is psoriatic arthritis, which has gained prominence due to the rising recognition of its systemic characteristics and the effect it has on patients' quality of life. Often, dermatologists and rheumatologists work together in top-tier medical facilities to provide coordinated treatment plans that tackle both skin and joint issues. This group heavily employs biologic medications, especially for patients who have extensive health insurance or are opting for high-quality private treatment. Initiatives for early detection and updated clinical practices have helped in the better management of psoriatic arthritis in the UAE healthcare landscape. The others category consists of rarer variations like guttate, pustular, inverse, and erythrodermic psoriasis, usually managed in specialized dermatology departments or advanced care institutions. Specialized clinics deliver tailored treatment options, merging phototherapy, systemic medications, and innovative biologics as needed. The diverse expatriate demographic in the country leads to a range of clinical symptoms, promoting customized treatment strategies. UAE psoriasis market according to type reflects a strong uptake of modern therapies, collaborative care strategies, and a high-quality healthcare setting that promotes thorough patient support.
UAE psoriasis treatment market by treatment type is divided into biologics drugs, systemic drugs, topical drugs, phototherapy and others. Biologics play a crucial role in the UAE psoriasis treatment landscape, highlighting the nation’s substantial investment in healthcare and the embrace of cutting-edge therapies. Premier dermatology clinics and private medical facilities generally prescribe biologics that target IL-17, IL-23, and TNF pathways for moderate to severe cases of psoriasis and psoriatic arthritis. Extensive insurance plans and access to high-quality healthcare enable patients to receive these innovative treatments sooner than in many other regional markets. There is also a rising interest in biosimilars as healthcare professionals look for cost-effective options while maintaining excellent treatment quality. Systemic medications, including methotrexate and cyclosporine, remain significant for managing psoriasis, especially for individuals moving between different stages of treatment or seeking more economical solutions. Topical treatments continue to be crucial for individuals with mild psoriasis and as a part of ongoing treatment, widely dispensed in dermatology clinics and available at local pharmacies. These therapies are often used alongside advanced treatments to enhance clinical results and reduce the occurrence of flare-ups. Phototherapy is available in specialized skin treatment centers that have the latest ultraviolet treatment technologies, offering a successful non-invasive alternative for individuals who do not need oral medications. The category labeled others consists of new types of oral small-molecule treatments and combination approaches that improve personalized care options. The treatment scene in the UAE showcases a high-quality and innovative atmosphere where cutting-edge biologics are available alongside traditional treatments, allowing dermatologists to customize care plans based on the severity of the condition, patient choices, and insurance options.
UAE psoriasis treatment market by distribution channel is divided into hospital pharmacies, retail pharmacies and e-commerce. Hospital pharmacies play a crucial role in distributing advanced therapies for psoriasis in the UAE, especially for biologic medicines that require a specialist's prescription and medical supervision. Prominent hospitals and specialized clinics oversee the beginning of treatment, dosing plans, and ongoing patient follow-up, ensuring the safe and effective administration of expensive medications. Coordinated healthcare systems enable patients to access consultations, diagnostic tests, and treatments all in one place, improving adherence to treatment and clinical results. Community pharmacies are vital in distributing topical medications, ongoing therapies, and widely used systemic drugs. The UAE’s large network of local pharmacies offers easy access to medications and provides patient counseling services that encourage adherence and effective long-term disease management. Pharmacists frequently work together with dermatologists to track treatment progress and inform patients about the right way to use their medicines, which leads to better health outcomes. E-commerce and online pharmacy services are quickly growing in the UAE because of high rates of digital engagement and the increasing acceptance of telehealth options. More patients are turning to online services to handle prescriptions, book consultations, and get medications delivered to their homes. Regulatory bodies ensure strict monitoring to verify prescriptions and maintain product quality. Teledermatology programs, which accelerated during and following the COVID-19 pandemic, have further strengthened digital distribution methods, especially for follow-up care and remote health monitoring. As digital health solutions continue to advance, e-commerce is likely to play a larger supportive role alongside hospital and retail pharmacy networks in the UAE psoriasis treatment system.
Make this report your own
Have queries/questions regarding a report
Take advantage of intelligence tailored to your business objective
Sikandar Kesari
Research Analyst
Considered in this report
* Historic Year: 2020
* Base year: 2025
* Estimated year: 2026
* Forecast year: 2031
Aspects covered in this report
* Psoriasis Treatment Market with its value and forecast along with its segments
* Various drivers and challenges
* On-going trends and developments
* Top profiled companies
* Strategic recommendation
By Type
Plaque Psoriasis
Psoriatic Arthritis
Others
Don't pay for what you don't need. Save 30%
Customise your report by selecting specific countries or regions
By Treatment Type
Biologics Drugs
Systemic Drugs
Topical Drugs
Phototherapy
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
e-Commerce
Table of Contents
1. Executive Summary
2. Market Structure
2.1. Market Considerate
2.2. Assumptions
2.3. Limitations
2.4. Abbreviations
2.5. Sources
2.6. Definitions
3. Research Methodology
3.1. Secondary Research
3.2. Primary Data Collection
3.3. Market Formation & Validation
3.4. Report Writing, Quality Check & Delivery
4. United Arab of Emirates Geography
4.1. Population Distribution Table
4.2. United Arab of Emirates Macro Economic Indicators
5. Market Dynamics
5.1. Key Insights
5.2. Recent Developments
5.3. Market Drivers & Opportunities
5.4. Market Restraints & Challenges
5.5. Market Trends
5.6. Supply chain Analysis
5.7. Policy & Regulatory Framework
5.8. Industry Experts Views
6. United Arab of Emirates Psoriasis Treatment Market Overview
6.1. Market Size By Value
6.2. Market Size and Forecast, By Type
6.3. Market Size and Forecast, By Treatment Type
6.4. Market Size and Forecast, By Distribution Channel
6.5. Market Size and Forecast, By Region
7. United Arab of Emirates Psoriasis Treatment Market Segmentations
7.1. United Arab of Emirates Psoriasis Treatment Market, By Type
7.1.1. United Arab of Emirates Psoriasis Treatment Market Size, By Plaque Psoriasis, 2020-2031
7.1.2. United Arab of Emirates Psoriasis Treatment Market Size, By Psoriatic Arthritis, 2020-2031
7.1.3. United Arab of Emirates Psoriasis Treatment Market Size, By Others, 2020-2031
7.2. United Arab of Emirates Psoriasis Treatment Market, By Treatment Type
7.2.1. United Arab of Emirates Psoriasis Treatment Market Size, By Biologics Drugs, 2020-2031
7.2.2. United Arab of Emirates Psoriasis Treatment Market Size, By Systemic Drugs, 2020-2031
7.2.3. United Arab of Emirates Psoriasis Treatment Market Size, By Topical Drugs, 2020-2031
7.2.4. United Arab of Emirates Psoriasis Treatment Market Size, By Phototherapy, 2020-2031
7.2.5. United Arab of Emirates Psoriasis Treatment Market Size, By Others, 2020-2031
7.3. United Arab of Emirates Psoriasis Treatment Market, By Distribution Channel
7.3.1. United Arab of Emirates Psoriasis Treatment Market Size, By Hospital Pharmacies, 2020-2031
7.3.2. United Arab of Emirates Psoriasis Treatment Market Size, By Retail Pharmacies, 2020-2031
7.3.3. United Arab of Emirates Psoriasis Treatment Market Size, By E-Commerce, 2020-2031
7.4. United Arab of Emirates Psoriasis Treatment Market, By Region
7.4.1. United Arab of Emirates Psoriasis Treatment Market Size, By North, 2020-2031
7.4.2. United Arab of Emirates Psoriasis Treatment Market Size, By East, 2020-2031
7.4.3. United Arab of Emirates Psoriasis Treatment Market Size, By West, 2020-2031
7.4.4. United Arab of Emirates Psoriasis Treatment Market Size, By South, 2020-2031
8. United Arab of Emirates Psoriasis Treatment Market Opportunity Assessment
8.1. By Type, 2026 to 2031
8.2. By Treatment Type, 2026 to 2031
8.3. By Distribution Channel, 2026 to 2031
8.4. By Region, 2026 to 2031
9. Competitive Landscape
9.1. Porter's Five Forces
9.2. Company Profile
9.2.1. Company 1
9.2.1.1. Company Snapshot
9.2.1.2. Company Overview
9.2.1.3. Financial Highlights
9.2.1.4. Geographic Insights
9.2.1.5. Business Segment & Performance
9.2.1.6. Product Portfolio
9.2.1.7. Key Executives
9.2.1.8. Strategic Moves & Developments
9.2.2. Company 2
9.2.3. Company 3
9.2.4. Company 4
9.2.5. Company 5
9.2.6. Company 6
9.2.7. Company 7
9.2.8. Company 8
10. Strategic Recommendations
11. Disclaimer
Table 1: Influencing Factors for Psoriasis Treatment Market, 2025
Table 2: United Arab of Emirates Psoriasis Treatment Market Size and Forecast, By Type (2020 to 2031F) (In USD Million)
Table 3: United Arab of Emirates Psoriasis Treatment Market Size and Forecast, By Treatment Type (2020 to 2031F) (In USD Million)
Table 4: United Arab of Emirates Psoriasis Treatment Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Million)
Table 5: United Arab of Emirates Psoriasis Treatment Market Size and Forecast, By Region (2020 to 2031F) (In USD Million)
Table 6: United Arab of Emirates Psoriasis Treatment Market Size of Plaque Psoriasis (2020 to 2031) in USD Million
Table 7: United Arab of Emirates Psoriasis Treatment Market Size of Psoriatic Arthritis (2020 to 2031) in USD Million
Table 8: United Arab of Emirates Psoriasis Treatment Market Size of Others (2020 to 2031) in USD Million
Table 9: United Arab of Emirates Psoriasis Treatment Market Size of Biologics Drugs (2020 to 2031) in USD Million
Table 10: United Arab of Emirates Psoriasis Treatment Market Size of Systemic Drugs (2020 to 2031) in USD Million
Table 11: United Arab of Emirates Psoriasis Treatment Market Size of Topical Drugs (2020 to 2031) in USD Million
Table 12: United Arab of Emirates Psoriasis Treatment Market Size of Phototherapy (2020 to 2031) in USD Million
Table 13: United Arab of Emirates Psoriasis Treatment Market Size of Others (2020 to 2031) in USD Million
Table 14: United Arab of Emirates Psoriasis Treatment Market Size of Hospital Pharmacies (2020 to 2031) in USD Million
Table 15: United Arab of Emirates Psoriasis Treatment Market Size of Retail Pharmacies (2020 to 2031) in USD Million
Table 16: United Arab of Emirates Psoriasis Treatment Market Size of e-Commerce (2020 to 2031) in USD Million
Table 17: United Arab of Emirates Psoriasis Treatment Market Size of North (2020 to 2031) in USD Million
Table 18: United Arab of Emirates Psoriasis Treatment Market Size of East (2020 to 2031) in USD Million
Table 19: United Arab of Emirates Psoriasis Treatment Market Size of West (2020 to 2031) in USD Million
Table 20: United Arab of Emirates Psoriasis Treatment Market Size of South (2020 to 2031) in USD Million
Figure 1: United Arab of Emirates Psoriasis Treatment Market Size By Value (2020, 2025 & 2031F) (in USD Million)
Figure 2: Market Attractiveness Index, By Type
Figure 3: Market Attractiveness Index, By Treatment Type
Figure 4: Market Attractiveness Index, By Distribution Channel
Figure 5: Market Attractiveness Index, By Region
Figure 6: Porter's Five Forces of United Arab of Emirates Psoriasis Treatment Market
United Arab Emirates Psoriasis Treatment Market Research FAQs
The primary treatment for psoriasis in the Middle East and Africa includes topical therapies like corticosteroids, vitamin D analogs, and increasingly, biologic agents for moderate to severe cases.
Biologic therapies have revolutionized psoriasis treatment by offering higher efficacy, particularly for severe cases, leading to broader adoption in the region as they provide more effective long-term management.
Plaque psoriasis is the most common due to its high visibility, easily recognizable symptoms, and prevalence across the region, with it accounting for the majority of diagnosed psoriasis cases.
Patients in the region face challenges such as high treatment costs, limited insurance coverage, and uneven access to dermatology care, particularly in rural and low-income areas.
Teledermatology has significantly improved access to care, especially in remote areas, allowing for virtual consultations and better monitoring of psoriasis treatments, improving continuity of care.
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information